Potentiation of nialamide-induced hypermotility in mice by lithium and the 5-HT uptake inhibitors chlorimipramine and FG 4963.
D000818:Animals; D000840:Anisoles / Q000494:pharmacology*; D002997:Clomipramine / Q000494:pharmacology*; D003984:Dibenzazepines / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D005260:Female; D010134:Fenclonine / Q000494:pharmacology; D008094:Lithium / Q000494:pharmacology*; D051379:Mice; D008815:Mice, Inbred Strains; D009043:Motor Activity / Q000187:drug effects*; D009526:Nialamide / Q000008:administration & dosage / Q000494:pharmacology*; D010880:Piperidines / Q000494:pharmacology*; D012701:Serotonin / Q000378:metabolism; D013268:Stimulation, Chemical; D013997:Time Factors; D014364:Tryptophan / Q000494:pharmacology
D000840:Anisoles; D003984:Dibenzazepines; D010880:Piperidines; D012701:Serotonin; D014364:Tryptophan; C010655:femoxetine; D008094:Lithium; D002997:Clomipramine; D010134:Fenclonine; D009526:Nialamide